Business Description
Nanologica AB
ISIN : SE0005454873
Total Employee Number:
72Compare
Compare
Traded in other countries / regions
NICA.Sweden4YD.Germany IPO Date
2015-10-30Description
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.33 | |||||
Equity-to-Asset | 0.37 | |||||
Debt-to-Equity | 1.22 | |||||
Debt-to-EBITDA | 2.74 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -0.76 | |||||
Beneish M-Score | -2.44 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 69.1 | |||||
3-Year EBITDA Growth Rate | 31.4 | |||||
3-Year EPS without NRI Growth Rate | 29.9 | |||||
3-Year FCF Growth Rate | 35.3 | |||||
3-Year Book Growth Rate | -49 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 24.85 | |||||
9-Day RSI | 30.74 | |||||
14-Day RSI | 37.38 | |||||
3-1 Month Momentum % | 45.26 | |||||
6-1 Month Momentum % | -21.35 | |||||
12-1 Month Momentum % | -51.16 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.15 | |||||
Quick Ratio | 0.8 | |||||
Cash Ratio | 0.33 | |||||
Days Inventory | 943.56 | |||||
Days Sales Outstanding | 63.16 | |||||
Days Payable | 287.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -32.7 | |||||
Shareholder Yield % | -19.66 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 61.8 | |||||
Operating Margin % | -153.52 | |||||
Net Margin % | 78.97 | |||||
EBITDA Margin % | 136.72 | |||||
FCF Margin % | -84.65 | |||||
OCF Margin % | -84.57 | |||||
ROE % | 45.53 | |||||
ROA % | 18.24 | |||||
ROIC % | -44.34 | |||||
3-Year ROIIC % | -17.77 | |||||
ROC (Joel Greenblatt) % | 54.05 | |||||
ROCE % | 32.46 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 1.64 | |||||
Forward PE Ratio | 5.02 | |||||
Price-to-Owner-Earnings | 1.04 | |||||
PS Ratio | 1.27 | |||||
PB Ratio | 0.56 | |||||
Price-to-Tangible-Book | 0.61 | |||||
EV-to-EBIT | 7.8 | |||||
EV-to-EBITDA | 5.41 | |||||
EV-to-Revenue | 7.41 | |||||
EV-to-Forward-Revenue | 14.48 | |||||
EV-to-FCF | -8.62 | |||||
Price-to-GF-Value | 0.11 | |||||
Price-to-Median-PS-Value | 0.06 | |||||
Earnings Yield (Greenblatt) % | 12.82 | |||||
FCF Yield % | -17.3 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nanologica AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 31.839 | ||
| EPS (TTM) (kr) | 0.274 | ||
| Beta | 1.1836 | ||
| 3-Year Sharpe Ratio | -0.86 | ||
| 3-Year Sortino Ratio | -1.08 | ||
| Volatility % | 113.9 | ||
| 14-Day RSI | 37.38 | ||
| 14-Day ATR (kr) | 0.040584 | ||
| 20-Day SMA (kr) | 0.51 | ||
| 12-1 Month Momentum % | -51.16 | ||
| 52-Week Range (kr) | 0.33 - 2.25 | ||
| Shares Outstanding (Mil) | 328.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nanologica AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nanologica AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-26 | In 134 days | ||
| Second quarter earnings results for 2026 | 2026-08-27 | In 43 days | ||
| General meeting for 2026 | 2026-05-21 10:00 | 0.65 (+10.92%) | ||
| First quarter earnings results for 2026 | 2026-05-20 | 0.49 (-2.58%) | ||
| Annual report for 2025 | 2026-04-24 | 0.62 (+24.65%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-06 | 0.39 (-1.24%) | ||
| Third quarter earnings results for 2025 | 2025-10-24 | 1.30 (-12.08%) | ||
| Second quarter earnings results for 2025 | 2025-07-11 | 1.17 (+0.85%) | ||
| General meeting for 2025 | 2025-05-22 12:00 | 1.21 (+1.24%) | ||
| First quarter earnings results for 2025 | 2025-04-17 | 0.92 (-7.03%) |
Show
Entries
Nanologica AB Frequently Asked Questions
What is Nanologica AB(OSTO:NICA)'s stock price today?
The current price of OSTO:NICA is kr0.45. The 52 week high of OSTO:NICA is kr2.25 and 52 week low is kr0.33.
When is next earnings date of Nanologica AB(OSTO:NICA)?
The next earnings date of Nanologica AB(OSTO:NICA) is 2026-08-27.
Does Nanologica AB(OSTO:NICA) pay dividends? If so, how much?
Nanologica AB(OSTO:NICA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Nanologica AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers